Reply to thread

Message: [QUOTE="greenmedinfo, post: 5494"] PMID: Leuk Res Rep. 2021 ;16:100281. Epub 2021 Nov 22. PMID: 34900576 Abstract Title: Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients. Abstract: Objective: High-dose ascorbic acid leads to the formation of highly reactive oxygen species due to the pro-oxidant effect, resulting in cell death; therefore, used as an additive treatment in several malignancies. We present the results obtained by administration of pharmacological dose of ascorbic acid to conventional chemotherapy in relapsed refractory multiple myeloma patients.Materials-methods: Intravenous ascorbic acid at a pharmacologic dose of 15 gram/week was added to the chemotherapy regimen of relapsed refractory multiple myeloma patients, who received carfilzomib-lenalidomide-dexamethasone treatment and did not respond after the second cycle.Results: The total of 4 patients who had previously received 6-9 lines of myeloma treatment were included. After 4 cycles of chemotherapy + ascorbic acid combination, 1 patient had a complete response whereas other patients had a very good partial response.Conclusion: The addition of pharmacological dose ascorbic acid to conventional chemotherapy can be an effective approach in relapsed refractory patients. Clinical studies with a large number of patients will be useful to evaluate the pharmacological dose of ascorbate in plasma cell disorders. [URL='https://www.greenmedinfo.com/article/pharmacological-dose-ascorbic-acid-administration-relapsed-refractory-multiple']read more[/URL] [/QUOTE]

Verification

Top Bottom

Search

Search

Reply to thread